Document Detail


Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
MedLine Citation:
PMID:  21284024     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical studies of tadalafil and other PDE5 inhibitors have reported significant symptom reduction but limited urinary flow rate improvement. This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.
METHODS: Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files. Articles were selected for review based on describing in vitro, preclinical, or clinical studies of pathological processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.
RESULTS: Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia. Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.
CONCLUSIONS: The pathophysiology of male LUTS is complex and not completely understood. LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap. While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS.
Authors:
Karl-Erik Andersson; William C de Groat; Kevin T McVary; Tom F Lue; Mario Maggi; Claus G Roehrborn; Jean Jacques Wyndaele; Thomas Melby; Lars Viktrup
Related Documents :
20957414 - Rhipicephalus sanguineus on dogs: relationships between attachment sites and tick devel...
23123604 - The "double wrist flexor" tendon transfer for radial nerve palsy.
21194154 - Reversible infantile respiratory chain deficiency: a clinical and molecular study.
14570144 - The use of a 4% (w/w) deltamethrin collar (scalibor protectorband) in the extended cont...
1553254 - Adaptation of energy metabolism of canine latissimus dorsi muscle in response to chroni...
19671494 - Muscle motion and emg activity in vibration treatment.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-01-31
Journal Detail:
Title:  Neurourology and urodynamics     Volume:  30     ISSN:  1520-6777     ISO Abbreviation:  Neurourol. Urodyn.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-17     Completed Date:  2011-06-30     Revised Date:  2012-08-10    
Medline Journal Info:
Nlm Unique ID:  8303326     Medline TA:  Neurourol Urodyn     Country:  United States    
Other Details:
Languages:  eng     Pagination:  292-301     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Wiley-Liss, Inc.
Affiliation:
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. karl-erik.andersson@klinfarm.lu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbolines / therapeutic use*
Evidence-Based Medicine
Humans
Male
Phosphodiesterase 5 Inhibitors / therapeutic use*
Prostatic Hyperplasia / complications*,  physiopathology
Recovery of Function
Signal Transduction / drug effects
Treatment Outcome
Urodynamics / drug effects
Urologic Diseases / drug therapy*,  etiology,  physiopathology
Chemical
Reg. No./Substance:
0/Carbolines; 0/Phosphodiesterase 5 Inhibitors; 0/tadalafil
Comments/Corrections
Comment In:
Neurourol Urodyn. 2012 Jun;31(5):706   [PMID:  22488565 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urinary diaries: Evidence for the development and validation of diary content, format, and duration.
Next Document:  Renal sympathetic nervous system hyperactivity in early streptozotocin-induced diabetic kidney disea...